8-K - CALLAN JMB INC. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Callan JMB Inc. reported a net loss of $7.97 million for the full year 2025, driven by increased SG&A expenses from its IPO and a revenue decline in emergency preparedness services, while announcing several strategic growth initiatives in healthcare and government logistics.

Key Takeaways

1Full-year 2025 revenue decreased to $5.7 million from $6.6 million in 2024 due to lower demand for emergency preparedness services from certain governments.

2Net loss widened to $7.97 million in 2025 from $2.29 million in 2024, primarily due to increased SG&A expenses related to becoming a public company.

3The company secured multiple growth agreements, including a manufacturing oversight deal with Attune Biotech and a joint venture with Revival Health.

4Emergency preparedness operations were strengthened with contract extensions in Chicago and Oregon, and the appointment of a former Chicago health official.

5Cash and cash equivalents were $2.13 million as of December 31, 2025, with the company having raised proceeds from its IPO and an ELOC facility.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

. Results of Operations and Financial Condition.** ** ** On March 31, 2026, Callan JMB Inc., a Nevada corporation (the “**Company**”) announced its financial re

Financial Results

9.01

Financial Statements and Exhibits.** ** ** (d) Exhibits. The following exhibits are being filed herewith: | Exhibit No. | | Description | |---|---|---| | 99.1 |

Exhibits Only

Source Document

Results of Operations

Full Year 2025

Metric	Value	Prior Period
Revenue	$5.72	$6.56
Gross Profit	$2.10	$2.56
Loss from Operations	$7.03	$2.27
Net Loss	$7.97	$2.29
Diluted EPS	$-1.82	$-0.87

Exhibits (2)

8-K

99.1

EX-99.1